Quantcast

Latest Tyrosine kinase inhibitors Stories

2010-06-17 16:34:00

Approval expands use in treatment of rare type of leukemia SILVER SPRING, Md., June 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed.

2010-06-09 06:00:00

SINGAPORE, June 9 /PRNewswire/ -- S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S.

2010-06-07 08:14:00

LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001).

2010-06-06 07:50:04

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy.

2010-06-06 07:45:27

Two drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication.

2010-06-06 07:28:27

Combination of targeted agent, chemotherapy improves progression-free survival; therapy inhibits both VEGFR and EGFR.

2010-06-04 00:23:00

EAST HANOVER, N.J., June 4 /PRNewswire/ -- Novartis announced today 18-month results (median follow-up) showing that Tasigna® (nilotinib) capsules significantly surpass the efficacy of Gleevec® (imatinib mesylate) tablets* in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase(1).

2010-05-20 17:00:00

SUNNYVALE, Calif., May 20 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the abstract it submitted for the Annual Meeting of the American Society of Clinical Oncology (ASCO), June 4-8, 2010 in Chicago, IL was released by ASCO today.

2010-05-20 07:00:00

NEW YORK, May 20 /PRNewswire-FirstCall/ -- Pfizer Oncology (NYSE: PFE) will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets.

2010-05-17 12:40:39

New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia.


Word of the Day
fleuron
  • an ornament or knob in the shape of a flower
  • In architecture, a floral ornament; specifically, the large conventional flower usually placed in the center of the abacus of a Corinthian capital or classic ceiling-caisson; also, the floreated termination of a Gothic finial.
[ "The word 'fleuron' comes from French."]